Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement.

Simona, Soverini; Alessandra, Gnani; Caterina De, Benedittis; Ilaria, Iacobucci; Annalisa, Lonetti; Cristina, Papayannidis; Leonardo, Potenza; Mario, Luppi; Serena, Merante; Malagola, Michele; Russo, Domenico; Mario, Tiribelli; Marzia, Salvucci; Alfonso, Zaccaria; Barbara, Giannini; Giovanni, Poletti; Antonella, Vitale; Loredana, Elia; Marco, Vignetti; Robin, Foà; Michele, Baccarani; Giovanni, Martinelli